Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05188508 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
A Phase 2 study of Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 10
- Study locations
NCT05188508 is a Phase 2 study of Glioma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 57 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (73% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT05188508, a Phase 2 study of Glioma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- COMBINATION_PRODUCT Olaparib and Temozolomide
Study Locations (10)
New York
- Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Connecticut
- Hartford Healthcare Alliance (Data Collection Only) - Hartford
Florida
- BAPTIST ALLIANCE - MCI (Data Collection Only) - Miami
Pennsylvania
- Lehigh Valley Health Network (Data Collection Only) - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2022-01-14 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05188508
The ClinicalTrials.gov registry entry for NCT05188508 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (73% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05188508 reports 10 study locations spanning 5 distinct geographic areas - top geographies include New York, New Jersey, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05188508 about?
NCT05188508 is a clinical study titled "Pembrolizumab, Olaparib, and Temozolomide for People With Glioma". This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
What is the current status of trial NCT05188508?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2022-01-14. Estimated completion is 2027-01.
What conditions does trial NCT05188508 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT05188508?
The interventions under investigation include: Pembrolizumab (DRUG), Olaparib and Temozolomide (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05188508?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05188508 being conducted?
This trial has 10 study locations across Connecticut, Florida, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Methimazole in Patients With Progressive Glioblastoma
RECRUITING · Phase 2
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
A Study Utilizing Escitalopram in Glioma Patients
RECRUITING · Phase 2
-
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.